Mineralys completes Launch-HTN enrollment ahead of schedule; topline data mid-H1 2025

Mineralys Therapeutics, Inc.

Enrollment completed ahead of schedule in global Phase 3 Launch-HTN trial of lorundrostat for uncontrolled or resistant hypertension.
Topline data now anticipated in mid first half of 2025, earlier than originally planned.
Trial randomized patients to placebo, lorundrostat 50 mg QD, or 50 mg titrated to 100 mg QD; primary endpoint SBP change at 6 weeks.
Company hosting virtual KOL event on Oct 30 to discuss unmet need and lorundrostat pivotal program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.